NASDAQ$BDTX
Black Diamond Therapeutics I · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
Reported third quarter financial results and provided a corporate update.
Black Diamond Therapeutics reported its third quarter 2023 financial results. The company's cash, cash equivalents, and investments totaled $144.3 million as of September 30, 2023, which is expected to fund operations into the first half of 2025. BDTX-1535 Phase 1 dose escalation data showed durable anti-tumor activity and favorable safety profile in NSCLC patients. The first patient was dosed in a Phase 1 trial of BDTX-4933.
- Presented BDTX-1535 Phase 1 dose escalation data showing durable anti-tumor activity and favorable safety profile in NSCLC patients.
- BDTX-1535 NSCLC expansion cohorts are enrolling, with initial data expected in 2024.
- Dosed first patient in a Phase 1 trial of BDTX-4933, a brain-penetrant RAF inhibitor targeting KRAS, NRAS and BRAF alterations in solid tumors.
- Cash, cash equivalents, and investments of $144.3 million as of September 30, 2023, expected to be sufficient to fund operations into the first half of 2025.
Headline financials
Revenue & EPS history
Black Diamond Therapeutics · Revenue · Quarterly
$334K
Forward guidance
Black Diamond believes its cash, cash equivalents and investments will be sufficient to fund its anticipated operating expenses and capital expenditure requirements into the first half of 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2023
-1.4%
Avg return
Earnings day
-0.1%
Avg return
5 days after
-1.6%
Avg return
30 days after
40%
10 / 25 earnings
Positive
+15.6%
Q4 2019
Best reaction
-19.6%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.5% | +0.0% | -30.5% | |
| Q4 2025 | +2.4% | -3.7% | +33.3% | |
| Q3 2025 | -8.1% | -1.5% | -31.4% | |
| Q1 2025 | +2.1% | +5.2% | +19.7% | |
| Q4 2024 | -1.8% | +4.1% | -15.8% | |
| Q3 2024 | +10.0% | +10.0% | -21.4% | |
| Q2 2024 | -14.0% | -12.5% | +5.3% | |
| Q1 2024 | -12.0% | -17.3% | -25.2% | |
| Q4 2023 | +4.8% | +19.7% | +39.3% | |
| Q3 2023 | -4.2% | -6.3% | +24.7% | |
| Q2 2023 | -3.5% | -9.7% | +2.3% | |
| Q1 2023 | -2.1% | -1.6% | +11.5% | |
| Q4 2022 | -19.6% | +3.6% | -3.0% | |
| Q3 2022 | -2.7% | +13.6% | -28.1% | |
| Q2 2022 | +4.5% | +4.3% | -21.8% | |
| Q1 2022 | -9.4% | -8.4% | +5.4% | |
| Q4 2021 | +8.2% | +7.8% | +16.4% | |
| Q3 2021 | +2.0% | -4.0% | -22.8% | |
| Q2 2021 | -1.8% | -1.3% | +4.3% | |
| Q1 2021 | -4.0% | +9.0% | -50.3% | |
| Q4 2020 | +2.1% | +0.7% | +19.0% | |
| Q3 2020 | +9.2% | +3.2% | +8.1% | |
| Q2 2020 | -9.2% | -11.4% | -11.6% | |
| Q1 2020 | -1.1% | -5.4% | -19.5% | |
| Q4 2019 | +15.6% | +0.4% | +51.7% | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro